Phase II trial exploring the combination of enzalutamide with five alpha-reductase inhibitors (ARIs) for castrate-sensitive prostate cancer. Driven by observations from geriatric oncology, the study seeks alternatives to androgen deprivation therapy (ADT) for older, frail men who struggle with its side effects. The trial examines whether enzalutamide combined with dutasteride or finasteride can effectively manage prostate cancer while avoiding ADT. The results are promising, showing a median PSA progression-free survival that was not reached, with many patients maintaining low PSA levels for several years. Despite side effects like fatigue and gynecomastia, the treatment is well tolerated. The study highlights the potential for using ARIs and enzalutamide in this vulnerable group, suggesting a shift towards less intensive therapies could benefit frail patients.
Source :